Clinical Trials | November 14, 2025
Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Encouraging early detection and breaking the silence around men’s health
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
